Similar articles

• Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

  Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A; Study 907 Team. Squires K, et al. Ann Intern Med. 2003 Sep 2;139(5 Pt 1):313-20. doi: 10.7326/0003-4819-139-5_part_1-200309020-00006. Ann Intern Med. 2003. PMID: 12965939 Clinical Trial.
• Tenofovir disoproxil fumarate.

  Antoniou T. Antoniou T. Drugs. 2003;63(15):1609-10. doi: 10.2165/00003495-200363150-00007. Drugs. 2003. PMID: 12887266 No abstract available.
• Tenofovir disoproxil fumarate.

  Kumar A. Kumar A. Drugs. 2003;63(15):1609-10. doi: 10.2165/00003495-200363150-00008. Drugs. 2003. PMID: 12887267 No abstract available.
• Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.

  Antoniou T, Park-Wyllie LY, Tseng AL. Antoniou T, et al. Pharmacotherapy. 2003 Jan;23(1):29-43. doi: 10.1592/phco.23.1.29.31915. Pharmacotherapy. 2003. PMID: 12523458 Review.
• The use of tenofovir disoproxil fumarate for the treatment of nucleoside-resistant HIV-1.

  McColl DJ, Miller MD. McColl DJ, et al. J Antimicrob Chemother. 2003 Feb;51(2):219-23. doi: 10.1093/jac/dkg109. J Antimicrob Chemother. 2003. PMID: 12562684 Review. No abstract available.